Develop and provide liquid biopsy-based blood tests for advanced stage cancer patients. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 27% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 27% a year on average.
The company sells $982.0M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $416.3M against $982.0M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 40/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, GH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GH has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.